**Supplementary Table 2.** Medications of the Patients Newly Receiving Alogliptin

|  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- |
| 　 | Time | age <65 | age 65-74 | age ≥75 | p | \* |
| Number of applicable patients | 0M | 110 | 87 | 93 | 　 | 　 |
| 12M | 100 | 79 | 84 | 　 | 　 |
|   DPP-4 inhibitors  | Before | 27 (24.5%) | 28 (32.2%) | 21 (22.6%) | 0.302  | 　 |
| 0M | 110 (100%) | 87 (100%) | 93 (100%) | N/A | 　 |
| 12M | 100 (100%) | 79 (100%) | 84 (100%) | N/A | 　 |
| Sulfonylurea | Before | 38 (34.5%) | 38 (43.7%) | 41 (44.1%) | 0.289  | 　 |
| 0M | 36 (32.7%) | 38 (43.7%) | 35 (37.6%) | 0.289  | 　 |
| 12M | 40 (40%) | 34 (43%) | 32 (38.1%) | 0.811  | 　 |
| Biguanide | Before | 36 (32.7%) | 20 (23%) | 14 (15.1%) | 0.013  | \* |
| 0M | 39 (35.5%) | 24 (27.6%) | 14 (15.1%) | 0.004  | \* |
| 12M | 50 (50%) | 24 (30.4%) | 17 (20.2%) | <0.001 | \* |
| Thiazolidine | Before | 28 (25.5%) | 12 (13.8%) | 18 (19.4%) | 0.125  | 　 |
| 0M | 22 (20%) | 14 (16.1%) | 16 (17.2%) | 0.758  | 　 |
| 12M | 22 (22%) | 9 (11.4%) | 15 (17.9%) | 0.178  | 　 |
| α-Glucosidase inhibitors | Before | 25 (22.7%) | 20 (23%) | 26 (28%) | 0.639  | 　 |
| 0M | 19 (17.3%) | 11 (12.6%) | 15 (16.1%) | 0.659  | 　 |
| 12M | 13 (13%) | 10 (12.7%) | 12 (14.3%) | 0.948  | 　 |
| Glinide | Before | 5 (4.5%) | 4 (4.6%) | 7 (7.5%) | 0.588  | 　 |
| 0M | 0 (0%) | 0 (0%) | 0 (0%) | N/A | 　 |
| 12M | 0 (0%) | 0 (0%) | 0 (0%) | N/A | 　 |
| Insulin | Before | 0 (0%) | 1 (1.1%) | 0 (0%) | 0.310  | 　 |
| 0M | 0 (0%) | 0 (0%) | 0 (0%) | N/A | 　 |
| 12M | 0 (0%) | 0 (0%) | 1 (1.2%) | 0.343  | 　 |

\*p<0.05 Chi-squared test.